Neurogene is accelerating development of new genetic medicines to people with devastating neurological diseases and their families. To do this, we are working with experts across the globe to advance a broad pipeline of programs to treat the underlying cause of serious neurological disorders and thereby address the overwhelming need for new therapies. Although the human genome was sequenced for the first time nearly 20 years ago, the true genomics revolution is taking place now, providing us with the ability to radically alter rare, genetic disorders. At Neurogene, we are working to provide medicines to improve the lives of neurologically-impaired and developmentally-delayed children and their families. We are building a team of passionate, driven individuals who envision a world in which all families have access to genetic medicines, even if the disorder is exceedingly rare. To learn more, please visit http://www.neurogene.com/careers/.
View Top Employees from Neurogene Inc.Website | http://www.neurogene.com |
Revenue | $45.6 million |
Funding | $183.5 million |
Employees | 95 (88 on RocketReach) |
Founded | 2018 |
Address | 535 W 24th St 5th Floor, New York, New York 10011, US |
Technologies |
JavaScript,
HTML,
PHP
+31 more
(view full list)
|
Industry | Biotechnology, Pharmaceuticals, Healthcare, Science and Engineering |
Competitors | Apic Bio, Inc., Lysosomal Therapeutics Inc., Ovid Therapeutics, Seelos Therapeutics, Inc. |
SIC | SIC Code 283 Companies, SIC Code 28 Companies |
NAICS | NAICS Code 325 Companies, NAICS Code 32541 Companies, NAICS Code 32 Companies, NAICS Code 3254 Companies |
Looking for a particular Neurogene Inc. employee's phone or email?
The Neurogene Inc. annual revenue was $45.6 million in 2024.
88 people are employed at Neurogene Inc..
Neurogene Inc. is based in New York, New York.
The NAICS codes for Neurogene Inc. are [325, 32541, 32, 3254].
The SIC codes for Neurogene Inc. are [283, 28].